Wilms Tumor 1 (WT1) Peptide Vaccine
Links: https://thejns.org/abstract/journals/j-neurosurg/108/5/article-p963.xml
From Ben Williams Book: In March of 2015, a Japanese group published results of a trial that tested a Wilms tumor 1(WT1) peptide vaccine in addition to radiation and chemotherapy for newly diagnosed glioblastoma (341). Wilms Tumor 1 (WT1) is a protein overexpressed in various types of solid and liquid cancers, not to be confused with the pediatric cancer it is named after (Wilms’ Tumor). Seven patients were included in the analysis, with four having undergone total tumor resection, two having partial resection, and one having biopsy only. None of the tumors were positive for IDH1 mutation. Patients received up to 24 monthly temozolomide cycles, the standard at this institution. Remarkably, five of these seven patients (71%) were still disease-free at three years or more. Only one patient had experienced disease progression at the time of analysis and all were still alive. Median progression-free and overall survival were at least 43.5 months (about 3 and a half years), which was the median follow-up time at the time of the analysis. These very impressive results were not likely simply due to the prolonged cycles of temozolomide: at the same institution, median PFS and OS with up to 24 cycles of TMZ (but no vaccine) is 10.7 and 21 months.
An abstract (reference 342, abstract IMCT-09) for the SNO 2015 meeting tells us that median progression-free survival for the seven patients is now over 48 months (4 years) as five of seven patients were still without progression at that time point.Property "Has original text" (as page type) with input value "In March of 2015, a Japanese group published results of a trial that tested a Wilms tumor</br>1(WT1) peptide vaccine in addition to radiation and chemotherapy for newly diagnosed</br>glioblastoma (341). Wilms Tumor 1 (WT1) is a protein overexpressed in various types of</br>solid and liquid cancers, not to be confused with the pediatric cancer it is named after</br>(Wilms’ Tumor). Seven patients were included in the analysis, with four having</br>undergone total tumor resection, two having partial resection, and one having biopsy</br>only. None of the tumors were positive for IDH1 mutation. Patients received up to 24</br>monthly temozolomide cycles, the standard at this institution. Remarkably, five of these</br>seven patients (71%) were still disease-free at three years or more. Only one patient had</br>experienced disease progression at the time of analysis and all were still alive. Median</br>progression-free and overall survival were at least 43.5 months (about 3 and a half years),</br>which was the median follow-up time at the time of the analysis. These very impressive</br>results were not likely simply due to the prolonged cycles of temozolomide: at the same</br>institution, median PFS and OS with up to 24 cycles of TMZ (but no vaccine) is 10.7 and</br>21 months.</br></br>An abstract (reference 342, abstract IMCT-09) for the SNO 2015 meeting tells us that</br>median progression-free survival for the seven patients is now over 48 months (4 years)</br>as five of seven patients were still without progression at that time point." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
